You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
葵花葯業(002737.SZ)業績快報:2019年度淨利潤升3.52%至5.83億元
格隆匯 02-25 16:07

格隆匯2月25日丨葵花葯業(002737.SZ)披露2019年度業績快報,實現營業總收入43.66億元,同比下降2.37%;營業利潤7.86億元,同比增長9.81%;利潤總額8.02億元,同比增長11.27%;歸屬於上市公司股東的淨利潤5.83億元,同比增長3.52%;基本每股收益1元。

報告期內,公司持續聚焦小葵花兒童藥核心戰略,進一步整合資源做戰略投入,豐富兒童藥戰略圍棋式的產品管線,形成對兒童常見病、常用藥的全面覆蓋。在此基礎上,公司確定以兒童常見病的呼吸系統、消化系統、礦維補益和營養保健品類搭建增長曲線,以兒童藥的持續增長構築品類競爭壁壘,擴大小葵花兒童藥在兒童用藥領域的領軍優勢。

公司以小葵花兒童藥品類為主,以婦科藥品類和老年慢病品類為輔,執行品類營銷策略,強化品牌引領,堅持核心主品打造,推進兒童藥、婦科用藥、老慢病用藥品類的協同發展。

在營銷推廣上,公司通過KA、直控、商控、電商四大平台的建設,不斷擴大終端覆蓋,並積極探索新零售銷售創新。報告期內,公司普藥模式全面推進管理模式變革,將事業部制管理模式轉變為大區制管理模式,實行片區化管理,進一步整合資源,貼近市場,下沉服務。

同時,通過營銷的精細化管理,提升費用效能;在生產過程中嚴格管控生產質量,加強成本管控,驅動公司利潤的持續增長。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account